A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

NCT06116786 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-small-Cell Lung

Interventions

DRUG: JNJ-86974680
DRUG: Cetrelimab
RADIATION: Radiation Therapy

Sponsor

Johnson & Johnson Enterprise Innovation Inc.